Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. - Wikidata - awgldk - TriplyDB

Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.

Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.

http://www.wikidata.org/entity/Q37678145

about

Understanding heart failure with preserved ejection fraction: where are we today?European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society Heart failure with preserved ejection fraction Advances in the management of heart failure: the role of ivabradine Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases Right heart dysfunction in heart failure with preserved ejection fraction Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular Performance Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction Left Atrial Structure and Function in Heart Failure with Preserved Ejection Fraction: A RELAX Substudy.Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction.Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy.The Challenge of Chamber Stiffness Determination in Chronic Atrial Fibrillation vs. Normal Sinus Rhythm: Echocardiographic Prediction with Simultaneous Hemodynamic Validation.Heart failure with preserved ejection fraction in the elderly: scope of the problem.Heart failure with preserved ejection fraction: current understandings and challenges.Almanac 2014: cardiovascular imaging.European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.Riociguat for the treatment of pulmonary hypertension.Heart Failure with Preserved Ejection Fraction in Older Adults.Targets for Heart Failure With Preserved Ejection Fraction.Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.Cardiac diastolic and autonomic dysfunction are aggravated by central chemoreflex activation in heart failure with preserved ejection fraction rats.Global left atrial failure in heart failure.CHADS2 and modified CHA2DS2-VASc scores for the prediction of congestive heart failure in patients with nonvalvular atrial fibrillation.Impact of Atrial Fibrillation on Exercise Capacity and Mortality in Heart Failure With Preserved Ejection Fraction: Insights From Cardiopulmonary Stress Testing.Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction.The importance of integrated left atrial evaluation: From hypertension to heart failure with preserved ejection fraction.Atrial remodelling in heart failure: recent developments and relevance for heart failure with preserved ejection fraction.Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction.Atrial fibrillation in heart failure with preserved ejection fraction: time to address the chicken and the egg.Atrial septal defect and exercise capacity: value of cardio-pulmonary exercise test in assessment and follow-up High-sensitivity C-reactive protein in heart failure with preserved ejection fraction

P2860

Q26766590-C4654AE4-DA6A-4383-9F32-77A582EB9284 Q26796261-FB59626E-EC9A-4881-BE7C-9F14B9CA55DD Q27024008-802347A2-B052-48F3-BC78-90C4D1963E0D Q28072418-74323870-C24D-478E-BB37-8769C30CB33B Q33565707-4E6D7E53-F12A-4839-BEA5-61CAA4D1DB10 Q35156618-D0EA6A41-A3CC-487B-99FC-ADFE5114CFC8 Q35588220-8C19B0AD-A4A4-41D6-A1EF-032677602882 Q35725839-1F727EB5-FAF6-4BAE-8EEA-043CD252C017 Q36181771-9E1B206D-D2E4-4194-A67F-C05FC439644D Q36182164-394DD521-C355-4655-9AF7-EDFAB473825B Q36535510-C2C0D4C5-C61B-4FED-8D29-91A92BFBE63F Q37408637-0A85BE7D-DACE-4DB9-9E6F-311A27EB7ABC Q37495698-877CDAAD-82D6-443D-9BC9-94C2D2C02FC9 Q37633991-28D2CBF3-26AC-46EB-9EA3-5BB2C05D915C Q38217344-00F691EB-08FE-48B0-B760-DC7B1CAB3A48 Q38259214-BF4D0C0E-C042-4FF3-92D2-4A1C781BD5F8 Q38571627-A90350E4-6E8C-4AAC-B505-8D12E3A14B10 Q38645382-7C12AA5D-CA7E-4F65-8B65-7EF1C3537105 Q38672337-E81E0A3B-2741-4F83-8B31-A248492B6CCC Q38688194-32BEB265-FFC7-412C-BCAE-169FE7D0A354 Q38743215-8B69EFBB-B5A2-40EA-8BA5-E1A2D1B66BD0 Q38970479-959FBB80-AC58-4A64-922E-DDA1D5C3AD35 Q38998559-300D4B77-2518-4CC4-B389-02716EAB79C1 Q42265923-B717F6E7-D98D-4B81-A434-9B9A582207D2 Q47162739-1364CB80-9850-42A4-8F18-185081FB44F6 Q47548712-B0B821B5-DB30-4325-B9EC-1579FF066ABD Q48337267-D3ADA32D-8FF6-4ED9-95EA-F3FDFBF492E0 Q49850138-0C310B51-D8D9-4987-83A5-A05473EB2CF4 Q50099011-3EED03C5-BF67-4BC3-98C7-0D35623AC993 Q50099027-D0FB9667-2E95-49CE-B1CA-D215EB278B13 Q57300719-D88A0828-9B12-47B7-9A06-82070055F610 Q58775176-988C0A2F-D0D4-4D50-9BC1-4AAF236BB576

P2860

Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.

http://www.wikidata.org/entity/Q37678145

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Impact of atrial fibrillation ...... a RELAX trial ancillary study.

@en

Impact of atrial fibrillation ...... a RELAX trial ancillary study.

@nl

type

label

Impact of atrial fibrillation ...... a RELAX trial ancillary study.

@en

Impact of atrial fibrillation ...... a RELAX trial ancillary study.

@nl

prefLabel

Impact of atrial fibrillation ...... a RELAX trial ancillary study.

@en

Impact of atrial fibrillation ...... a RELAX trial ancillary study.

@nl

P1433

Q37678145-3F922B0F-C39F-4F95-AA50-704E45074872

P1476

Q37678145-310951D2-A7FB-465D-91D7-D699D72648AF

P2093

Q37678145-37B23363-D4E3-440A-8A2E-565D64A09CF6

Q37678145-586DCFE6-4B65-4255-89CE-D0D7F9B0520C

Q37678145-678723C4-DE9F-47C3-9B2D-02EC0570F77A

Q37678145-8D484150-C911-4467-855F-DFFEAE7A40DF

Q37678145-A38ADB6E-A072-4B1A-992F-D89C8803438A

Q37678145-B3545EDE-626E-4F71-8426-57AD7BB06902

Q37678145-CB790DF7-413A-4181-876B-D5505455240B

Q37678145-EB8FBBFE-D77C-495F-AFB7-1DFCA40B1E76

Q37678145-EF0C2899-E4F7-4E50-AF30-583D82E98555

P2860

Q37678145-0343F7BD-1BF6-47C9-B4DF-D665BCCA0FDD

Q37678145-0381FC1D-0747-46CD-BD79-7B7A1AC62B76

Q37678145-03CCE064-3544-469B-BDF1-A4AB1DB0FDBC

Q37678145-122C3603-86EF-45E2-8773-129E5147D35E

Q37678145-378132C5-AFC7-4BFA-ABE9-095CABE4D384

Q37678145-3D4525E0-EE96-4BE2-AE04-98558C212120

Q37678145-44B26CC8-75E4-413A-974A-2E61FA0D7E4C

Q37678145-453A547D-DF16-44EB-91E0-1BF9CEA6708A

Q37678145-46BD41DC-F487-4082-B120-7DF51D4382EB

Q37678145-55CC2766-B060-4862-8EFC-A45E2EFC442E

P304

Q37678145-EFE36A58-ACC7-4839-842D-F33846164C7B

P31

Q37678145-26A998B0-369F-4237-9047-E8E42ABBE5FA

P356

Q37678145-296E6D75-EDC4-424A-8F28-A86961F2F5B1

P433

Q37678145-1CCFB858-2B1D-476B-BBDB-82D1B161D042

P478

Q37678145-A91F2ED4-6C5C-4CC6-AB98-7D7FBB30889D

P50

Q37678145-09FC5832-9391-4B3F-A54B-048819AB888A

Q37678145-85C8A406-42E4-4B58-9A2E-7EFB74CA0C7D

P577

Q37678145-A843002F-D777-4D30-ABF8-51C678A8429D

P698

Q37678145-BEF2EB0D-B0E0-4E95-9CBA-2EF391CE028D

P921

Q37678145-290F2545-A40D-458F-A419-7BED7A069B32

Q37678145-A87A2AE7-3871-4459-898A-E3731EC13836

P932

Q37678145-7320E526-3083-480A-B548-2E59B1CFE37A

P356

CIRCHEARTFAILURE.113.000568

P1433

Circulation: Heart Failure

P1476

Impact of atrial fibrillation ...... a RELAX trial ancillary study.

@en

P2093

Anita Deswal

http://www.w3.org/2001/XMLSchema#string

Barry A Borlaug

http://www.w3.org/2001/XMLSchema#string

Gregory D Lewis

http://www.w3.org/2001/XMLSchema#string

Marc J Semigran

http://www.w3.org/2001/XMLSchema#string

Margaret M Redfield

http://www.w3.org/2001/XMLSchema#string

Martin LeWinter

http://www.w3.org/2001/XMLSchema#string

Rosita Zakeri

http://www.w3.org/2001/XMLSchema#string

Selma F Mohammed

http://www.w3.org/2001/XMLSchema#string

Steven E McNulty

http://www.w3.org/2001/XMLSchema#string

P2860

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Rhythm control versus rate control for atrial fibrillation and heart failure.

Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy.

Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction.

Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients.

Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study.

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Determining the preferred percent-predicted equation for peak oxygen consumption in patients with heart failure.

Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis.

PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design.

P304

123-130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCHEARTFAILURE.113.000568

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Eugene Braunwald

Adrian F. Hernandez

P577

2013-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24162898

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

3972021

http://www.w3.org/2001/XMLSchema#string